Kailei Chen

Union Hospital
Wuhan, 430022, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

CA9-Targeted PET Imaging for Noninvasive Discrimination of Clear Cell Renal Cell Carcinoma and Associated Tumor Biological Features.

CA9-Targeted PET Imaging for Noninvasive Discrimination of Clear Cell Renal Cell Carcinoma and Associated Tumor Biological Features.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: February 23, 2026

PRKAB2 as a tumor suppressor in renal cell carcinoma: inhibiting mitophagy via the LRPPRC-PRKN/parkin interaction and cardiolipin biosynthesis.

PRKAB2 as a tumor suppressor in renal cell carcinoma: inhibiting mitophagy via the LRPPRC-PRKN/parkin interaction and cardiolipin biosynthesis.

Journal: Autophagy

Published: January 30, 2026

Recent progress on tyrosine kinase inhibitors resistance in renal cell carcinoma: another brick in the wall?

Recent progress on tyrosine kinase inhibitors resistance in renal cell carcinoma: another brick in the wall?

Journal: Cancer drug resistance (Alhambra, Calif.)

Published: August 01, 2025

Mitochondrial SLC25A10 promotes prostate cancer progression by inhibiting ferritinophagy.

Mitochondrial SLC25A10 promotes prostate cancer progression by inhibiting ferritinophagy.

Journal: Cell death discovery

Published: January 09, 2025

Exploring the Effects of Opioid-Related Drugs on the Clinical Outcome of Prostate Cancer Patients Via Integrated Bioinformatics Analysis.

Exploring the Effects of Opioid-Related Drugs on the Clinical Outcome of Prostate Cancer Patients Via Integrated Bioinformatics Analysis.

Journal: Molecular biotechnology

Published: April 16, 2024

A mitochondrion-targeted cyanine agent for NIR-II fluorescence-guided surgery combined with intraoperative photothermal therapy to reduce prostate cancer recurrence.

A mitochondrion-targeted cyanine agent for NIR-II fluorescence-guided surgery combined with intraoperative photothermal therapy to reduce prostate cancer recurrence.

Journal: Journal of nanobiotechnology

Published: February 18, 2024

MIER2/PGC1A elicits sunitinib resistance via lipid metabolism in renal cell carcinoma.

MIER2/PGC1A elicits sunitinib resistance via lipid metabolism in renal cell carcinoma.

Journal: Journal of advanced research

Published: February 04, 2024

Clinical value of molecular subtypes identification based on anoikis-related lncRNAs in castration-resistant prostate cancer.

Clinical value of molecular subtypes identification based on anoikis-related lncRNAs in castration-resistant prostate cancer.

Journal: Cellular signalling

Published: October 01, 2023

circRARS synergises with IGF2BP3 to regulate RNA methylation recognition to promote tumour progression in renal cell carcinoma.

circRARS synergises with IGF2BP3 to regulate RNA methylation recognition to promote tumour progression in renal cell carcinoma.

Journal: Clinical and translational medicine

Published: May 21, 2023

Overall survival and cancer-specific survival were improved in local treatment of metastatic prostate cancer.

Overall survival and cancer-specific survival were improved in local treatment of metastatic prostate cancer.

Journal: Frontiers in oncology

Published: December 23, 2022

External fixation in the treatment of displaced supracondylar femoral fracture in children: A retrospective case series.

External fixation in the treatment of displaced supracondylar femoral fracture in children: A retrospective case series.

Journal: Acta orthopaedica et traumatologica turcica

Published: March 02, 2022

Restoring the epigenetically silenced lncRNA COL18A1-AS1 represses ccRCC progression by lipid browning via miR-1286/KLF12 axis.

Restoring the epigenetically silenced lncRNA COL18A1-AS1 represses ccRCC progression by lipid browning via miR-1286/KLF12 axis.

Journal: Cell death & disease

Published: December 03, 2021

Showing 1-12 of 16

Last Updated: 09/26/2026